8 research outputs found
m-TOR inhibitors may be useful in the treatment of encapsulating peritoneal sclerosis (EPS).
Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication of long-term peritoneal dialysis, often occurring after patients have been shifted to haemodialysis or undergone renal transplantation. EPS is still associated with high morbidity and mortality but, although various treatment modalities have been tried, the optimal therapy is still debated. The present paper reports a 16-year-old patient who developed EPS 6 months after shifting to haemodialysis and, following adhesiolysis, was successfully treated with a combination of steroids, tamoxifen and everolimus, this last drug chosen for its antiproliferative effect through mammalian target of rapamycin (mTOR) inhibition and its ability to block vascular endothelial growth factor and neoangiogenesis. EPS progressively improved and the patient successfully underwent renal transplantation 5 years later. The case suggests that, in view of their mechanism of action, mTOR inhibitors should be considered as an immunosuppressive agent after renal transplantation in patients at risk and merit investigation in future trials on this condition
Safety and efficacy of denosumab in severe osteoporotic hemodialysed patients and kidney transplant recipients: case series.
Venous thromboembolism in renal transplant recipients: Results of Venous thromboEmbolism in renal Transplant Recipients- Italian Study - VETRIS
none15noN.A. (Letter)mixedPoli D.; Migliaccio L.; Antonucci E.; Biancone L.; Bozzolin A.; Corradetti V.; Finale C.; Furian L.; La Manna G.; Larti A.; Ranghino A.; Rossetti M.M.; Taruscia D.; Palareti G.; Zanazzi M.Poli D.; Migliaccio L.; Antonucci E.; Biancone L.; Bozzolin A.; Corradetti V.; Finale C.; Furian L.; La Manna G.; Larti A.; Ranghino A.; Rossetti M.M.; Taruscia D.; Palareti G.; Zanazzi M
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Renal Transplant Patients: Preliminary Results From NEVERWOUND Study
Immediate Introduction of Everolimus Does Not Affect Wound Healing and Delayed Graft Function in Renal Transplant Patients: Preliminary Results From NEVERWOUND Study.
Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN
Membranoproliferative GN (MPGN) was recently reclassified as alternative pathway complement-mediated C3 glomerulopathy (C3G) and immune complex-mediated membranoproliferative GN (IC-MPGN). However, genetic and acquired alternative pathway abnormalities are also observed in IC-MPGN. Here, we explored the presence of distinct disease entities characterized by specific pathophysiologic mechanisms. We performed unsupervised hierarchical clustering, a data-driven statistical approach, on histologic, genetic, and clinical data and data regarding serum/plasma complement parameters from 173 patients with C3G/IC-MPGN. This approach divided patients into four clusters, indicating the existence of four different pathogenetic patterns. Specifically, this analysis separated patients with fluid-phase complement activation (clusters 1-3) who had low serum C3 levels and a high prevalence of genetic and acquired alternative pathway abnormalities from patients with solid-phase complement activation (cluster 4) who had normal or mildly altered serum C3, late disease onset, and poor renal survival. In patients with fluid-phase complement activation, those in clusters 1 and 2 had massive activation of the alternative pathway, including activation of the terminal pathway, and the highest prevalence of subendothelial deposits, but those in cluster 2 had additional activation of the classic pathway and the highest prevalence of nephrotic syndrome at disease onset. Patients in cluster 3 had prevalent activation of C3 convertase and highly electron-dense intramembranous deposits. In addition, we provide a simple algorithm to assign patients with C3G/IC-MPGN to specific clusters. These distinct clusters may facilitate clarification of disease etiology, improve risk assessment for ESRD, and pave the way for personalized treatment